FOIA: OHRP Investigation – Brigham and Woment’s Hospital
FOIA: OHRP Investigation – Brigham and Women’s Hospital
Letter page one:
Letter page 2:
Letter page 3:
Similar Posts
Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs
Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs Thu, 18 Nov 2004 The Associated Press reports that at a Congressional hearing today, Dr. David Graham a drug safety expert at the FDA told the Senate Finance Committee that the public is “virtually defenseless” if another medication such as Vioxx…
Congressional Investigation of NIH: Cash Gifts From Grantees
Congressional Investigation of NIH: Cash Gifts From Grantees Tue, 8 Jul 2003 The Scientist reports that a Congressional committee is investigating the for “possible violations of federal criminal and ethics laws” involving Richard Klausner (former director of the National Cancer Institute) and other officials who accepted “lecture awards” and other…
Ethics of U Penn surgical "drug implant" experiment
Ethics of U Penn surgical “drug implant” experiment Tuesday, October 07 Notwithstanding a legion of prominent bioethicists at major universities such as the University of Pennsylvania and Johns Hopkins University, researchers at these institutions are not deterred from engaging in high risk human experimentation whose ethics are questionable. One has…
Forest Labs Admits Concealment of data – Congressional Probe Expands
Forest Labs Admits Concealment of data – Congressional Probe Expands Sat, 26 Jun 2004 New York Times business reporter, Barry Meier, reports, “Forest officials had not told a medical journal about a failed unpublished study in 2002 of Celexa use in children and adolescents, before the journal published an article…
Statement of the AHRP Opposing the SACHRP Children’s Committee Recommendations
The Alliance for Human Research Protection (AHRP) welcomes the opportunity to respond to the question “What is the Best Way to Protect Children?”
Our recommendation – which is backed up by evidence that children have suffered harm in medical research – is to significantly limit the discretion of IRBs to approve greater than minimal risk research without direct benefit for the child-subjects under 46.406.
We recommend staying the course in requiring that any such proposed experiment undergo a transparent open evaluation with ample opportunity for public oversight and comment – as required under the provisions of 46.407.
AHRP Letter to the editor re: editorial ARDS trial
AHRP Letter to the editor re: editorial ARDS trial July 10, 2003. The New England Journal of Medicine. Volume 349:188-192 Number 2 http://content.nejm.org/cgi/content/extract/349/2/188 Note: The April 3, 2003 the NEJM contained an editorial in support of a controversial multi-site, clinical trial sponsored by the National Heart, Lung, and Blood Institute…